We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Potential Biomarker Found for Sudden Infant Death Syndrome

By LabMedica International staff writers
Posted on 23 May 2022

The term Sudden Unexpected Death in Infancy (SUDI) covers both explained and unexplained deaths. More...

The unexplained deaths are termed Sudden Infant Death Syndrome (SIDS). Despite intensive studies over the past decades, the mechanisms which lead to SIDS remain elusive.

It is currently believed that SIDS is not due to a single factor, but is multi-factorial in origin. Acetylcholine (ACh) is a major neurotransmitter of the autonomic nervous system and the principal neurotransmitter of the parasympathetic nervous system. It is hydrolyzed at cholinergic synapses by two enzymes, Acetylcholinesterase (AChE), and Butyrlycholinesterase (BChE) (also known as pseudocholinesterase).

Clinical Scientists at the Children's Hospital at Westmead (Westmead, Australia) analyzed 722 dried blood samples (DBS) including 67 DBS (58% male) from SUDI infants (26 SIDS and 41 Non-SIDS), and 655 date of birth- and gender-matched controls: SIDS cases, mean age-at death 15.7 (± 8·1) weeks, (4-35 weeks), 54% male and Non-SIDS cases, mean age at death 31.7 (± 30) weeks, (1-103 weeks), 64% male.

Total BChE for each sample was quantified using the DetectX Butyrylcholinesterase Fluorescent Activity Kit (Arbor Assays, Ann Arbor, MI, USA) and the signal was read at 510nm with excitation at 390nm. Total protein in each sample was quantified using the BCA (Bicinchoninic acid) Dual Range Protein Detection Kit (Arbor Assays). The specific activity of BChE (BChEsa) was calculated by dividing BChE activity (mU/mL) by the total protein content (µg/ml) giving BChEsa in mU/µg. Results were reported in U/mg.

The investigators reported that conditional logistic regression showed that in groups where cases were reported as “SIDS death” there was strong evidence that lower BChE specific activity (BChEsa) was associated with death (OR=0.73 per U/mg, 95% CI 0.60-0.89), whereas in groups with a “Non-SIDS death” as the case there was no evidence of a linear association between BChEsa and death (OR=1.001 per U/mg, 95% CI 0.89-1.13).

The authors concluded that BChEsa, measured in dried blood spots taken 2-3 days after birth, was lower in babies who subsequently died of SIDS compared to surviving controls and other Non-SIDS deaths. They concluded that a previously unidentified cholinergic deficit, identifiable by abnormal-BChEsa, is present at birth in SIDS babies and represents a measurable, specific vulnerability prior to their death. The study was published on May 06, 2022 in the journal EBioMedicine.

Related Links:
Children's Hospital at Westmead 
Arbor Assays 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.